# Longevity science

Rating: Speculative — Little primary evidence yet: mechanism, anecdote or tradition
Type: Guide
Updated: 2026-10-14
Canonical: https://heretic.bio/articles/longevity-science-overview.html

> Longevity science targets the biological processes of aging itself, organized around the 12 hallmarks framework. The evidence pyramid is clear: exercise, sleep, diet and social connection have the strongest mortality data, while pharmaceuticals like rapamycin and metformin show safety and biomarker signals but nothing on human lifespan or healthspan endpoints. The best human trials so far, PEARL for rapamycin and TRIIM for epigenetic-age reversal, are small, short and surrogate-based.

> Aging is not inevitable — it is a biological process with identifiable mechanisms that can be modulated. The "hallmarks of aging" framework identifies 12 interconnected processes that drive biological decline. Interventions targeting these hallmarks — from [rapamycin](rapamycin-mtor-inhibition-pearl-trial-evidence-and-clinical-translation.html) to [dietary patterns](fasting-approaches.html) to [senescent cell clearance](senolytics.html) — are moving from animal studies into human clinical trials. As of 2026, **four pillars of human longevity RCT evidence** have matured: PEARL (rapamycin), TAME (metformin, still pre-recruitment), TRIIM-X (epigenetic reprogramming cocktail), and a wave of biological-age-clock reversal trials.  
  
## The Aging Problem

### Lifespan vs. Healthspan

  * **Lifespan:** Total years alive. Has increased dramatically (from ~47 in 1900 to ~79 in 2024 in the US)
  * **Healthspan:** Years lived in good health. Has NOT kept pace — ~10-15 years of disability precede death for most
  * **The goal is NOT immortality — it's compressing morbidity** into the shortest possible period at the end of life ("compression of morbidity" — Fries 1980; JAMA PMID [6773612](https://pubmed.ncbi.nlm.nih.gov/6773612/))



### The Economics of Aging

  * Chronic disease accounts for ~90% of US healthcare spending ($4.5 trillion/year, CDC 2024)
  * The pharmaceutical industry profits from managing (not curing) age-related disease
  * This creates perverse incentives against prevention and longevity research
  * The 2024 US National Strategy to Support Family Caregivers estimates informal caregiving costs at ~$470B/year if paid



## The Hallmarks of Aging (2023 Update + 2024 Commentary)

The current 12-hallmark taxonomy was published by López-Otín, Blasco, Partridge, Serrano, Kroemer in _Cell_ 2023 (PMID [36599349](https://pubmed.ncbi.nlm.nih.gov/36599349/)). It expands the original 2013 framework with three new hallmarks: **disabled macroautophagy** , **chronic inflammation (inflammaging)** , and **dysbiosis**.

# | Hallmark | Description | Key Intervention  
---|---|---|---  
1 | **Genomic instability** | DNA damage accumulation | NAD+ optimization, DNA repair support  
2 | **Telomere attrition** | Chromosome end shortening | Telomerase activation  
3 | **Epigenetic alterations** | DNA methylation changes | Peptide bioregulators, reprogramming factors  
4 | **Loss of proteostasis** | Protein misfolding/aggregation | Autophagy induction  
5 | **Deregulated nutrient sensing** | mTOR/AMPK dysregulation | Rapamycin, metformin  
6 | **Mitochondrial dysfunction** | Declining energy production | CoQ10, NAD+, exercise  
7 | **Cellular senescence** | "Zombie cells" that secrete inflammatory factors | Dasatinib+quercetin, fisetin  
8 | **Stem cell exhaustion** | Declining regenerative capacity | Stem cell therapy  
9 | **Altered intercellular communication** | Inflammatory signaling (SASP) | Anti-inflammatory protocols  
10 | **Disabled macroautophagy** | Impaired cellular recycling | Fasting, spermidine  
11 | **Chromatin reorganization** | Nuclear architecture changes | Under investigation  
12 | **Inflammaging** \+ **Dysbiosis** | Chronic low-grade inflammation + microbiome shift | Anti-inflammatory, diet, probiotics  
  
**2024 follow-up commentary** (Tartiere, Freije, López-Otín, _Front Aging_ 5:1334261) emphasizes that the 12 hallmarks should be viewed as **interdependent** rather than independent — e.g., senescent cells drive inflammaging, which accelerates epigenetic drift. A Copenhagen 2022 summary (Schmauck-Medina et al., _Aging_ 14:6829) proposed additional candidates: altered mechanical properties, splicing dysregulation. None have been formally adopted.

> **For the deep-dive canonical reference, see[Hallmarks of Aging - Canonical Framework](hallmarks-of-aging.html)** — 21KB, primary-source PMIDs for each hallmark, 2024 Tartière/Freije/López-Otín evaluation of new candidates, hierarchical organization, cross-species validation evidence, and connection to all library topic pages.

## The Longevity Intervention Hierarchy (Updated 2026)

### Tier 1: Lifestyle (Strongest Evidence, Highest Return)

  1. Exercise — VO2max and grip strength are the strongest predictors of all-cause mortality (Mandsager et al. _JAMA Netw Open_ 2018, PMID [30646320](https://pubmed.ncbi.nlm.nih.gov/30646320/); Kodama et al. _JAMA_ 2009, PMID [19349377](https://pubmed.ncbi.nlm.nih.gov/19349377/))
  2. Sleep — 7-9 hours, circadian alignment; short sleep associated with ~12% increased all-cause mortality (Cappuccio et al. _Sleep_ 2010, PMID [20469800](https://pubmed.ncbi.nlm.nih.gov/20469800/))
  3. Nutrition — Species-appropriate, metabolically healthy; Mediterranean diet has Class I evidence for cardiovascular and cognitive endpoints
  4. Fasting/Time-restricted eating — Autophagy activation, insulin reduction
  5. Social connection and purpose — Holt-Lunstad meta-analyses (2010, _PLoS Med_ PMID [20668659](https://pubmed.ncbi.nlm.nih.gov/20668659/)) show social isolation is equivalent to smoking 15 cigarettes/day in mortality risk



### Tier 2: Supplements (Moderate Evidence)

  6. NAD+ precursors (NMN/NR) — see also [NAD+ Precursors and Telomere Biology - Evidence Audit](nad-and-sirtuin-activators.html)
  7. Vitamin D3, magnesium, omega-3, creatine
  8. Spermidine, urolithin A — autophagy and mitophagy inducers with human biomarker data
  9. CoQ10, PQQ, alpha-lipoic acid



### Tier 3: Pharmaceutical (Growing Evidence)

  10. Rapamycin — best-characterized human longevity drug. **PEARL RCT** (Moel et al. _Aging_ 2025, PMID [40188830](https://pubmed.ncbi.nlm.nih.gov/40188830/)) showed 48-week safety + lean mass/pain signals in women at 5–10 mg weekly. **RAPA-EX-01** (Stanfield et al. _J Cachexia Sarcopenia Muscle_ 2026, PMID [41985884](https://pubmed.ncbi.nlm.nih.gov/41985884/)) flagged a key caveat: 6 mg/week **attenuated** exercise-induced hypertrophy in older adults.
  11. Metformin — AMPK activation, TAME trial (Barzilai et al., planned 3000 subjects, still pre-recruitment as of Aug 2026 per AFAR); 2025 critical review (Keys et al. _Ageing Res Rev_ PMID [40582648](https://pubmed.ncbi.nlm.nih.gov/40582648/)) questions strength of observational evidence
  12. Low-dose lithium — epidemiological longevity data (Kessing et al. _Br J Psychiatry_ 2008); small RCT signals in mild cognitive impairment
  13. Senolytic protocols (D+Q, fisetin) — first human senolytic trial: Justice et al. _EBioMedicine_ 2019 (PMID [30678418](https://pubmed.ncbi.nlm.nih.gov/30678418/)) showed D+Q reduced senescent cells in idiopathic pulmonary fibrosis patients



### Tier 4: Advanced/Experimental

  14. Telomerase activation (TA-65, epitalon)
  15. Stem cell therapies
  16. Plasma exchange / parabiosis factors — limited human data; Borsky et al. 2025 found 4–8 rounds of plasmapheresis **increased** DunedinPACE and GrimAge, contrary to the original Conboy mouse parabiosis hypothesis (PMID: see _Front Genet_ 2026 review)
  17. **Partial epigenetic reprogramming** — see [Partial Epigenetic Reprogramming - Competitive Intelligence](partial-epigenetic-reprogramming.html). The TRIIM-X trial (2025, ongoing, completion Dec 2025) reported interim 20% increase in physical fitness and reduced body fat using a growth-hormone / DHEA / metformin cocktail originally piloted as the TRIIM trial (Fahy et al. _Aging Cell_ 2019, PMID [30676660](https://pubmed.ncbi.nlm.nih.gov/30676660/)), which showed 1.5–2.5 years epigenetic age reversal on GrimAge.
  18. Gene therapy approaches



## Key Concepts in Longevity Science

### Biological Age vs. Chronological Age

  * **Epigenetic clocks** now span four generations:
  * 1st gen (chronological): Horvath 2013 (PMID [24138928](https://pubmed.ncbi.nlm.nih.gov/24138928/)), Hannum 2013 (PMID [24138928](https://pubmed.ncbi.nlm.nih.gov/24138928/))
  * 2nd gen (mortality-trained): PhenoAge (Levine 2018, PMID [29676998](https://pubmed.ncbi.nlm.nih.gov/29676998/)), GrimAge (Lu 2019, PMID [30669119](https://pubmed.ncbi.nlm.nih.gov/30669119/)), GrimAge2
  * 3rd gen (pace): DunedinPACE (Belsky 2022, PMID [35021509](https://pubmed.ncbi.nlm.nih.gov/35021509/)) — measures _rate_ of aging
  * 4th gen (causal): AdaptAge, CausAge, DamAge (Yan et al. 2024–25)
  * **GrimAge** remains the most predictive single static estimator of mortality
  * **DunedinPACE** is now preferred for intervention trials because it captures change over short intervals
  * Biological age can differ from chronological age by ±10-20 years; **modifiable**



### The Longevity Escape Velocity Concept

  * Proposed by Aubrey de Grey: If we can extend healthspan faster than time passes, we reach "escape velocity"
  * Each year of life, medical advances add more than one year of healthspan
  * Controversial but not physically impossible; requires sustained ~20% per-decade healthspan improvement



### The Dogma of "Aging as Disease"

  * WHO ICD-11 lists "aging-associated decline" as an extension code (XT9T) — not a primary disease
  * US FDA does not recognize aging as an indication (5-year precedent: rejected BioAge/Altos Longevity submissions)
  * If aging were reclassified, reimbursement pathways and trial design would change dramatically
  * The TAME trial is structured to **establish precedent** for aging as a composite endpoint (cardiovascular events + cancer + dementia + mortality)



## Human Trial Evidence — Snapshot, September 2026

Trial | Intervention | Status | Key Result | Source  
---|---|---|---|---  
**PEARL** | Rapamycin 5/10 mg weekly, 48 wk | Completed 2025 | Safe; women: ↑ lean mass, ↓ pain | Moel et al., PMID [40188830](https://pubmed.ncbi.nlm.nih.gov/40188830/)  
**RAPA-EX-01** | Sirolimus 6 mg/wk + exercise, 16 wk | April 2026 | Safety OK; **attenuated** hypertrophy | Stanfield et al., PMID [41985884](https://pubmed.ncbi.nlm.nih.gov/41985884/)  
**TRIIM** | GH + DHEA + metformin, 1 yr | Completed 2019 | GrimAge ↓1.5–2.5 yr | Fahy et al., PMID [30676660](https://pubmed.ncbi.nlm.nih.gov/30676660/)  
**TRIIM-X** | Same + lifestyle, larger cohort | Ongoing, est. Dec 2025 | Interim: ↑ fitness, ↓ fat | Drug Discov World Nov 2025  
**TAME** | Metformin, 3000 subjects, 6 yr | Pre-recruitment, partial funding | — | AFAR 2026  
**EVEROLIMUS (Mannick)** | mTOR inhibition in elderly | Completed 2014, 2018 | ↑ immune response to flu vaccine | Mannick et al., PMID [25215462](https://pubmed.ncbi.nlm.nih.gov/25215462/)  
**First senolytic (D+Q)** | Senolytic in IPF | Completed 2019 | Improved 6-min walk, chair-stands | Justice et al., PMID [30678418](https://pubmed.ncbi.nlm.nih.gov/30678418/)  
**Semaglutide + HIV lipohypertrophy** | GLP-1 RA | Preprint 2025 | Slowed epigenetic aging | Corley et al. 2025 medRxiv  
**Bezisterim (NS-1/3)** | p38 MAPK in early AD | 2025 | ↓ biological age acceleration | Reading et al., _Front Neurosci_ 2025  
  
## Cross-Cutting Caveats (2024-2026 Findings)

  1. **Exercise interaction:** mTORC1 inhibitors taken close to resistance training blunt hypertrophy (RAPA-EX-01, PMID [41985884](https://pubmed.ncbi.nlm.nih.gov/41985884/)). Proposed workaround: 3–6-week interdose intervals.
  2. **Clock interpretation:** Multiple clocks (DunedinPACE, PC GrimAge, PhenoAge) often **disagree** on the same intervention (Frontiers in Genetics 2026 review). Trust directional concordance, not single-clock p-values.
  3. **Plasmapheresis negative signal:** Borsky et al. 2025 showed increased aging pace — murine parabiosis benefit does not translate.
  4. **Rapamycin formulation bioavailability:** Compounded rapamycin in PEARL had ~⅓ bioavailability of branded sirolimus — the dose actually delivered was lower than labeled.
  5. **Cohort effects:** Longevity-trial volunteers (PEARL, TRIIM) are health-conscious, well-educated, baseline low-burden — generalizability to typical aging populations is limited.



## Longevity and Anti-Aging — Index

> The science of extending healthspan — compressing morbidity and optimizing the aging process itself. This section covers the hallmarks of aging, intervention mechanisms, the evidence for pharmaceutical and nutraceutical approaches, and practical protocols for targeting biological aging.

### Why Longevity Science Has Transformed

Aging is the primary driver of chronic disease:

Disease | Age as Primary Risk Factor  
---|---  
**Heart disease** | #1 cause of death; risk doubles each decade after 45  
**Cancer** | Exponential increase with age; median diagnosis age 66  
**Neurodegeneration** | Alzheimer's, Parkinson's — strongly age-dependent  
**Type 2 diabetes** | Age + metabolic dysfunction; often reversible  
**Sarcopenia** | 3-8% muscle loss per decade after 30  
  
The longevity field has shifted from "anti-aging" (a cosmetic framing) to **targeting aging biology itself** as the root cause of multiple chronic diseases simultaneously:

  * **不再是"抗衰老"** — Now "targeting the biology of aging" as a disease-modifying strategy
  * **Clinical trials emerging** — Senolytics, rapamycin, metformin, GLP-1 agonists
  * **Biomarkers validated** — Epigenetic clocks (Horvath, GrimAge), glycolytic shift markers
  * **Investment surge** — Altos Labs, Calico, Unity Biotechnology, multiple longevity biotech IPOs
  * **Regulatory recognition** — FDA considering "aging" as an indication for drug approval



### The Goal: Healthspan, Not Just Lifespan

The target is not maximum lifespan (the record, Jeanne Calment at 122) but **healthspan** : \- More years in good health \- Reduced disability and disease \- Maintained function and vitality \- Compressed morbidity at end of life

The difference between lifespan and healthspan in developed nations is often **10-15 years of morbidity**. Closing this gap is the central goal.

### Foundational

File | Description | Status | Size  
---|---|---|---  
[Overview - Longevity Science](longevity-science-overview.html) | Hallmarks of aging, intervention hierarchy, biological frameworks | Good | 5.8KB  
[Hallmarks of Aging - Canonical Framework](hallmarks-of-aging.html) | **Canonical 12-hallmark deep-dive** — 2013/2023 evolution, 2024 Tartière evaluation, three criteria, hierarchical organization, candidate hallmarks rejected, cross-references | Excellent | 21.3KB  
[NAD+ IV Therapy](nad-and-sirtuin-activators.html) | NAD+ pharmacokinetics, IV vs. oral precursors, clinical evidence | Excellent | 21.8KB  
[Biological Age Clocks - Measurement and Interpretation](biological-age-clocks-measurement-and-interpretation.html) | Clock generations, Dec 2025–Mar 2026 validation trilogy, intervention ledger, testing guide | Excellent | 10.4KB  
  
### Intervention Pillars

File | Description | Status | Size  
---|---|---|---  
[Autophagy](autophagy.html) | Cellular recycling mechanism, activation strategies, disease applications | Good | 4.6KB  
[Metformin and Rapamycin](metformin-and-rapamycin.html) | Leading pharmaceutical longevity candidates; TAME trial | Excellent | 13.7KB  
[NAD+ and Sirtuin Activators](nad-and-sirtuin-activators.html) | NAD+ decline, NMN/NR supplementation, sirtuin science | Good | 5.5KB  
[Senolytics](senolytics.html) | Clearing senescent "zombie" cells: D+Q, fisetin, quercetin | Good | 4.9KB  
[Telomere Science](telomere-science.html) | Telomere biology, telomerase activation, epitalon evidence | Good | 5.1KB  
[SGLT2 Inhibitors as Senotherapeutics](sglt2-inhibitors-as-senotherapeutics-evidence-taxonomy.html) | Anti-diabetic drug class with anti-senescence biology; first drug RCT to lengthen human telomeres (henagliflozin 2025); honest risk ledger incl. female-mouse lifespan reduction | Excellent | 9.2KB  
[mTOR and AMPK Pathways](mtor-and-ampk-pathways.html) | The growth/repair metabolic master switches | Good | 5.9KB  
[Klotho - The Longevity Hormone](klotho-the-longevity-hormone.html) | Longevity hormone: biology, mortality associations, primate cognition data, gene-therapy pipeline | Excellent | 11.9KB  
[Taurine - The Aging Amino Acid](taurine-the-aging-amino-acid.html) | Age-related decline hypothesis refuted by 2025 NIA longitudinal study; hormetic supplementation (1.5–4 g/day) trials (TauAge/TOP), NLRP3 mechanism, cardiometabolic meta-analyses | Excellent | 22.8KB  
  
### Hallmarks of Aging — The Intervention Framework

The nine hallmarks of aging (López-Otín et al., 2013; updated 2023) provide the primary organizing framework for longevity interventions. Each hallmark represents a distinct type of biological damage that accumulates with age:

### Primary Hallmarks (Direct Damage)

Hallmark | Description | Key Interventions  
---|---|---  
**1\. Genomic instability** | DNA damage accumulation from replication errors, ROS, UV, environmental toxins | NAD+ precursors (PARP support), resveratrol/sirtuins, DNA repair optimization  
**2\. Telomere attrition** | Chromosome end shortening with each cell division | Exercise, stress reduction, epitalon (Russian), astragalus  
**3\. Epigenetic alterations** | DNA methylation changes, histone modifications, loss of heterochromatin | Caloric restriction, rapamycin, NAD+ precursors  
  
### Antagonistic Hallmarks (Responses to Damage)

Hallmark | Description | Key Interventions  
---|---|---  
**4\. Loss of proteostasis** | Protein quality control decline; misfolded proteins accumulate | Autophagy inducers (rapamycin, spermidine, urolithin A), heat shock  
**5\. Deregulated nutrient sensing** | mTOR/AMPK/insulin/IGF-1 signaling disruption | Rapamycin (mTOR), metformin (AMPK), caloric restriction, protein restriction  
**6\. Mitochondrial dysfunction** | Energy production decline, ROS, metabolites | Urolithin A, NAD+ precursors, CoQ10, exercise, cold/heat  
  
### Integrative Hallmarks (Consequences of Above)

Hallmark | Description | Key Interventions  
---|---|---  
**7\. Cellular senescence** | "Zombie cells" accumulate, secrete SASP | Senolytics: dasatinib + quercetin, fisetin, GLP-1 agonists  
**8\. Stem cell exhaustion** | Regenerative capacity declines | Rapamycin, growth hormone/IGF-1 modulation, exercise  
**9\. Altered intercellular communication** | Inflammatory signaling, senescence-associated secretory phenotype (SASP) | Senolytics, metformin, omega-3s, anti-inflammatory lifestyle  
  
The framework matters because it helps explain _why_ interventions work — and why combination therapy targeting multiple hallmarks is likely more effective than any single intervention.

### 1\. Senolytics — Clearing Zombie Cells

Senescent cells resist apoptosis and secrete the SASP (pro-inflammatory cytokines, growth factors, proteases), creating a pro-inflammatory, pro-cancer microenvironment.

**The senolytic strategy** : Selectively induce apoptosis in senescent cells while leaving healthy cells intact.

Senolytic | Mechanism | Evidence Level | Notes  
---|---|---|---  
**Dasatinib + Quercetin (D+Q)** | Dasatinib: kinase inhibitor; Quercetin: senolytic flavonoid; synergistic | Moderate (early human trials) | Best-studied combination;间歇性 dosing  
**Fisetin** | Multiple mechanisms; strong in vitro data | Moderate | 20mg/kg in mice = ~150mg human; natural polyphenol  
**Quercetin alone** | Weaker senolytic than D+Q or fisetin | Lower | May work better as adjuvant  
**Navitoclax** | Bcl-2 family inhibitor | Early | Not clinically available  
**FOXO4-DRI** | p53 pathway inhibitor | Preclinical only | Peptide; not clinically available  
  
**Evidence status** : Phase 2 human trials in idiopathic pulmonary fibrosis (IPF) and diabetic kidney disease show senolytics reduce senescent cell burden. IPF trial showed improved physical function (6-minute walk distance) in 11/14 participants. Safety profile acceptable with intermittent dosing.

**Important caveats** : \- Long-term safety unknown (senescent cells have tumor suppression function) \- Biomarkers of senescence burden not yet standardized for clinical use \- Dosing is still being refined

See [Senolytics](senolytics.html) for detailed protocols.

### 2\. mTOR Inhibition — The Rapamycin Case

mTOR (mechanistic target of rapamycin) is the master nutrient-sensing kinase that: \- Activates protein synthesis (growth) \- Inhibits autophagy (cellular cleaning) \- Drives cellular senescence and SASP

Rapamycin (sirolimus) is an mTOR inhibitor originally used as an immunosuppressant transplant drug. It is the **most effective pharmacological longevity intervention in model organisms** (yeast, worms, flies, mice).

**Mouse data** : Rapamycin extends median lifespan 10-26% in mice even when started at the equivalent of 60 human years. It improves cardiac function, cognitive function, immune function, and reduces multiple age-related pathologies simultaneously.

**Human data** : No RCTs for longevity indication yet. Off-label use is widespread in the longevity community. The TAME (Targeting Aging with Metformin) trial will test metformin, rapamycin, and other interventions as combination therapy.

See [Rapamycin Dosing Protocols](rapamycin-mtor-inhibition-pearl-trial-evidence-and-clinical-translation.html) and [Metformin and Rapamycin](metformin-and-rapamycin.html) for detailed protocols and evidence evaluation.

### 3\. Autophagy Enhancement

Autophagy ("self-eating") is the cellular recycling process that clears damaged organelles, misfolded proteins, and intracellular pathogens. It declines with age, allowing damage to accumulate.

**Autophagy inducers** :

Compound | Mechanism | Evidence  
---|---|---  
**Rapamycin/sirolimus** | mTOR inhibition | Strong (pharmacological)  
**Spermidine** | mTOR inhibition; autophagy gene activation | Moderate (epidemiological + preclinical)  
**Urolithin A** | Mitophagy (mitochondrial autophagy) | Moderate (human RCTs)  
**Resveratrol** | Sirtuin activation → autophagy | Moderate (preclinical dominant)  
**Fasting (16+ hours)** | AMPK activation, insulin drop | Strong (mechanistic)  
**Exercise** | AMPK activation, autophagy induction | Strong  
  
**The fasting connection** : The most powerful natural autophagy inducer is fasting — 16+ hours without food. Overnight fasting (12-14 hours) produces some autophagy; 24-48 hour fasts produce more dramatic effects. The protein signaling (leucine, mTOR) must drop sufficiently.

See [Autophagy](autophagy.html) for detailed protocols.

### 4\. NAD+ Restoration

NAD+ declines ~50% from age 20 to 50. It's the central cofactor for: \- **Sirtuins** (1-7) — deacetylases linked to mitochondrial biogenesis, DNA repair, stress resistance \- **PARPs** — DNA repair enzymes; chronic DNA damage consumes NAD+ \- **CD38/CD157** — ectoenzymes that degrade NAD+; rise with inflammation/aging

See [NAD+ and Sirtuin Activators](nad-and-sirtuin-activators.html) and [NAD+ IV Therapy](nad-and-sirtuin-activators.html).

### 5\. Metformin

The most widely prescribed type 2 diabetes drug, with potential longevity benefits:

Aspect | Details  
---|---  
**Mechanism** | AMPK activation, mTOR inhibition, reduced insulin/IGF-1 signaling, anti-inflammatory  
**Evidence** | T2D patients on metformin show reduced all-cause mortality and cancer incidence in observational studies  
**TAME trial** | Targeting Aging with Metformin — multi-arm trial targeting aging biomarkers  
**Dosing** | —  
**Pros** | Cheap, well-understood safety, available, good evidence for diabetes  
**Cons** | GI side effects, B12 deficiency, not as potent as rapamycin for longevity  
  
See [Metformin and Rapamycin](metformin-and-rapamycin.html) for detailed comparison.

### Evidence Level by Intervention

Intervention | Preclinical Evidence | Human Evidence | Clinical Status  
---|---|---|---  
**Rapamycin** | Very strong (lifespan in multiple species) | Off-label use; no RCTs yet | Experimental for longevity  
**Metformin** | Moderate | Observational (T2D); TAME trial underway | Approved for T2D; off-label common  
**Senolytics (D+Q, fisetin)** | Strong | Early phase human trials | Experimental  
**NMN/NR** | Strong | Small human studies (NAD+ elevation) | Supplements; no FDA approval  
**Urolithin A** | Moderate | Human RCTs (gut, muscle) | Supplement available  
**Spermidine** | Moderate | Epidemiological (dietary) + some trials | Supplement; dietary sources  
**Autophagy (fasting/exercise)** | Very strong | Extensive observational | Widely practiced  
**Epitalon** | Moderate | Limited Russian human studies | Not FDA-approved; supplement  
**Telomerase activation** | Limited | No proven human telomere lengthening | Controversial  
  
### Uses

The longevity field is prone to extreme recommendations. The practical hierarchy:

**Step 0: Measure baseline** \- Blood work: CBC, metabolic panel, lipids, HbA1c, fasting insulin, vitamin D, hs-CRP \- Consider: epigenetic age (Horvath clock), telomere length (controversial) \- Physical: VO2max, body composition (DEXA), grip strength

### Biomarkers to Track

Category | Biomarkers | Frequency  
---|---|---  
**Metabolic** | Fasting insulin, HbA1c, triglycerides, HDL | 2x/year  
**Inflammatory** | hs-CRP, IL-6, TNF-α | 1-2x/year  
**Cardiovascular** | Lp(a), ApoB, homocysteine | 1x/year  
**Body composition** | DEXA scan | 1x/year  
**Fitness** | VO2max, grip strength | 1x/year  
**Epigenetic** | Epigenetic age clocks | 1x/year  
**Organ-specific** | Kidney function, liver enzymes | 2x/year  
  
### Connection to Other Sections

  * [Overview - Biohacking and Optimization](biohacking-and-optimization-overview.html) — Applied longevity protocols
  * [Overview - Therapeutic Peptides](therapeutic-peptides.html) — Epitalon (telomere), CJC-1295 (GH), BPC-157 (healing)
  * [Overview - Optimal Human Nutrition](optimal-human-nutrition-overview.html) — Fasting, caloric restriction, protein for longevity
  * [Mitochondrial Health](mitochondrial-health.html) — Central to aging; urolithin A, NAD+ precursors
  * [Autophagy](autophagy.html) — Detailed autophagy mechanisms and fasting protocols
  * [Sleep Optimization](sleep-optimization.html) — Sleep is a longevity intervention (glymphatic clearance, growth hormone)
  * [Senolytics](senolytics.html) — Detailed senolytic protocols
  * [Metformin and Rapamycin](metformin-and-rapamycin.html) — Pharmaceutical longevity interventions



### Notes

The longevity field has moved from fringe to mainstream in the past decade, but human evidence for most interventions lags far behind animal evidence. The strongest human evidence is for: 1\. **Exercise** (Zone 2 + strength) — no supplement comes close 2\. **Sleep** — glymphatic clearance is nightly maintenance 3\. **Rapamycin** — despite no human RCTs, the mechanism is compelling and animal data is overwhelming 4\. **Metformin** — usable now for those with metabolic dysfunction; TAME trial will clarify

The most promising near-term clinical developments: \- TAME trial results (expected 2026-2027) \- GLP-1 agonists (semaglutide) for obesity/mortality \- Senolytic Phase 3 trials (IPF, kidney disease) \- Epigenetic reprogramming ( Altos Labs, Calico)

The biggest risks in the longevity space: \- Supplement hype exceeding evidence (NR/NMN pricing >> evidence) \- Pharma-industry capture of "longevity" as a marketing term \- Unregulated "longevity clinics" selling expensive, unproven protocols \- Ignoring the foundations (exercise, sleep, diet) for expensive interventions

## Sources

1. PubMed 6773612 (PubMed 6773612)
2. López-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G. Hallmarks of aging: An expanding universe. Cell . 2023 Jan 19;186(2):243-278. PMID 36599349 (PubMed 36599349)
3. Mandsager K, Harb S, Cremer P, Phelan D, Nissen SE, Jaber WA. Association of cardiorespiratory fitness with long-term mortality among adults undergoing exercise treadmill testing. JAMA Netw Open . 2018;1(6):e183605. PMID 30646320 (PubMed 30646320)
4. PubMed 19349377 (PubMed 19349377)
5. PubMed 20469800 (PubMed 20469800)
6. Holt-Lunstad J, Smith TB, Layton JB. Social relationships and mortality risk: a meta-analytic review. PLoS Med . 2010;7(7):e1000316. PMID 20668659 (PubMed 20668659)
7. Moel M, et al. PEARL trial. Aging (Albany NY) . 2025;17(4):908-936. PMID 40188830 (PubMed 40188830)
8. Stanfield B, et al. RAPA-EX-01. J Cachexia Sarcopenia Muscle . 2026;17(2):e70274. PMID 41985884 (PubMed 41985884)
9. PubMed 40582648 (PubMed 40582648)
10. Justice JN, et al. Senolytics in idiopathic pulmonary fibrosis. EBioMedicine . 2019;40:554-563. PMID 30678418 (PubMed 30678418)
11. Fahy GM, et al. Reversal of epigenetic aging and immunosenescent trends in humans. Aging Cell . 2019;18(6):e13028. PMID 30676660 (PubMed 30676660)
12. Horvath S. DNA methylation age of human tissues. Genome Biol . 2013;14(R115). PMID 24138928 (PubMed 24138928)
13. PubMed 29676998 (PubMed 29676998)
14. Lu AT, Quach A, Wilson JG, et al. DNA methylation GrimAge strongly predicts lifespan and healthspan. Aging . 2019;11(2):303-327. PMID 30669119 (PubMed 30669119)
15. PubMed 35021509 (PubMed 35021509)
16. PubMed 25215462 (PubMed 25215462)
17. Tartiere AG, Freije JMP, López-Otín C. The hallmarks of aging as a conceptual framework for health and longevity research. Front Aging . 2024;5:1334261. doi 10.3389/fragi.2024.1334261 (DOI 10.3389/fragi.2024.1334261)
18. Barzilai N, Crandall JP, Kritchevsky SB, Espeland MA. Metformin as a Tool to Target Aging. Cell Metab . 2016;23(6):1060-1065. PMID 27304507 (PubMed 27304507)